QR-010

DRUG2 trials

Sponsors

ProQR Therapeutics

Conditions

Cystic Fibrosis

Phase 1

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

CompletedNCT02532764

ProQR TherapeuticsCystic Fibrosis

Start: 2015-06-30End: 2017-09-14Updated: 2019-02-06

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

CompletedNCT02564354

ProQR TherapeuticsCystic Fibrosis

Start: 2015-09-30End: 2016-09-30Updated: 2020-09-24